Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarin has successfully completed a preclinical proof of concept study using a novel nasal formulation of lorazepam.
Subscribe to our email newsletter
The preclinical study evaluated the extent of absorption of lorazepam after nasal administration and the pharmacokinetics of the novel formulation. Amarin is working with a subsidiary of Elan to prepare this nasal formulation for human pharmacokinetic trials.
This nasal lorazepam formulation utilizes Elan’s proprietary NanoCrystal technology and is in development for the out-patient treatment of emergency seizures in epilepsy patients, specifically status epilepticus and acute repetitive seizures.